Fresenius SE & Co. KGaA
(until January 28, 2011: Fresenius SE)

Consolidated Segment reporting

by business segment


  Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate/Other1 Fresenius Group
€ in millions 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change
1 Including special items from the acquisition of APP Pharmaceuticals, Inc.

The consolidated segment reporting by business segment is an integral part of the notes. The following notes are an integral part of the consolidated financial statements.
Sales 9,091 8,064 13% 3,672 3,086 19% 2,520 2,416 4% 713 618 15% -24 -20 -20% 15,972 14,164 13%
thereof contribution to consolidated sales 9,088 8,061 13% 3,629 3,046 19% 2,520 2,416 4% 713 618 15% 22 23 -4% 15,972 14,164 13%
thereof intercompany sales 3 3 0% 43 40 8% 0 0   - - -- -46 -43 -7% 0 0  
contribution to consolidated sales 57% 57%   23% 22%   16% 17%   4% 4%   0% 0%   100% 100%  
EBITDA 1,830 1,586 15% 893 742 20% 318 286 11% 49 42 17% -33 -40 18% 3,057 2,616 17%
Depreciation and amortization 379 327 16% 156 135 16% 83 81 2% 8 6 33% 13 13 0% 639 562 14%
EBIT 1,451 1,259 15% 737 607 21% 235 205 15% 41 36 14% -46 -53 13% 2,418 2,054 18%
Net interest -211 -215 2% -279 -302 8% -55 -55 0% 2 3 -33% -23 -11 -109% -566 -580 2%
Income taxes -436 -352 -24% -142 -89 -60% -37 -32 -16% -12 -12 0% 46 33 39% -581 -452 -29%
Net income attributable to Fresenius SE & Co. KGaA 738 639 15% 294 200 47% 131 107 22% 30 27 11% -571 -479 -19% 622 494 26%
                                     
Operating cash flow 1,032 960 8% 567 397 43% 311 219 42% 47 29 62% -46 -52 12% 1,911 1,553 23%
Cash flow before acquisitions and dividends 649 557 17% 401 272 47% 150 95 58% 38 24 58% -60 -57 -5% 1,178 891 32%
                                     
Total assets 12,793 10,982 16% 6,860 6,335 8% 3,270 3,199 2% 549 456 20% 105 -90 -- 23,577 20,882 13%
Debt 4,400 3,865 14% 4,298 4,184 3% 1,096 1,099 0% 16 2 -- -1,026 -851 -21% 8,784 8,299 6%
Capital expenditure, gross 395 411 -4% 174 125 39% 166 124 34% 9 5 80% 14 6 133% 758 671 13%
Acquisitions, gross 596 138 -- 31 32 -3% 13 79 -84% 5 2 150% -1 9 -111% 644 260 148%
                                     
Research and development expenses 73 67 9% 143 129 11% - - -- 0 0   28 44 -36% 244 240 2%
Employees (per capita on balance sheet date) 77,442 71,617 8% 22,851 21,872 4% 33,321 33,364 0% 3,110 2,849 9% 828 808 2% 137,552 130,510 5%
                                     
Key figures                                    
EBITDA margin 20.1% 19.7%   24.3% 24.0%   12.6% 11.8%   6.9% 6.8%         19.1% 18.5%  
EBIT margin 16.0% 15.6%   20.1% 19.7%   9.3% 8.5%   5.8% 5.8%         15.1% 14.5%  
Depreciation and amortization in % of sales 4.2% 4.1%   4.2% 4.4%   3.3% 3.4%   1.1% 1.0%         4.0% 4.0%  
Operating cash flow in % of sales 11.4% 11.9%   15.4% 12.9%   12.3% 9.1%   6.6% 4.7%         12.0% 11.0%  
ROOA 12.5% 12.2%   11.9% 10.2%   7.8% 7.1%   22.2% 22.8%         11.6% 10.5%  

  Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed Corporate/Other1 Fresenius Group
€ in millions 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change
1 Including special items from the acquisition of APP Pharmaceuticals, Inc.

The consolidated segment reporting by business segment is an integral part of the notes. The following notes are an integral part of the consolidated financial statements.
Sales 9,091 8,064 13% 3,672 3,086 19% 2,520 2,416 4% 713 618 15% -24 -20 -20% 15,972 14,164 13%
thereof contribution to consolidated sales 9,088 8,061 13% 3,629 3,046 19% 2,520 2,416 4% 713 618 15% 22 23 -4% 15,972 14,164 13%
thereof intercompany sales 3 3 0% 43 40 8% 0 0   - - -- -46 -43 -7% 0 0  
contribution to consolidated sales 57% 57%   23% 22%   16% 17%   4% 4%   0% 0%   100% 100%  
EBITDA 1,830 1,586 15% 893 742 20% 318 286 11% 49 42 17% -33 -40 18% 3,057 2,616 17%
Depreciation and amortization 379 327 16% 156 135 16% 83 81 2% 8 6 33% 13 13 0% 639 562 14%
EBIT 1,451 1,259 15% 737 607 21% 235 205 15% 41 36 14% -46 -53 13% 2,418 2,054 18%
Net interest -211 -215 2% -279 -302 8% -55 -55 0% 2 3 -33% -23 -11 -109% -566 -580 2%
Income taxes -436 -352 -24% -142 -89 -60% -37 -32 -16% -12 -12 0% 46 33 39% -581 -452 -29%
Net income attributable to Fresenius SE & Co. KGaA 738 639 15% 294 200 47% 131 107 22% 30 27 11% -571 -479 -19% 622 494 26%
                                     
Operating cash flow 1,032 960 8% 567 397 43% 311 219 42% 47 29 62% -46 -52 12% 1,911 1,553 23%
Cash flow before acquisitions and dividends 649 557 17% 401 272 47% 150 95 58% 38 24 58% -60 -57 -5% 1,178 891 32%
                                     
Total assets 12,793 10,982 16% 6,860 6,335 8% 3,270 3,199 2% 549 456 20% 105 -90 -- 23,577 20,882 13%
Debt 4,400 3,865 14% 4,298 4,184 3% 1,096 1,099 0% 16 2 -- -1,026 -851 -21% 8,784 8,299 6%
Capital expenditure, gross 395 411 -4% 174 125 39% 166 124 34% 9 5 80% 14 6 133% 758 671 13%
Acquisitions, gross 596 138 -- 31 32 -3% 13 79 -84% 5 2 150% -1 9 -111% 644 260 148%
                                     
Research and development expenses 73 67 9% 143 129 11% - - -- 0 0   28 44 -36% 244 240 2%
Employees (per capita on balance sheet date) 77,442 71,617 8% 22,851 21,872 4% 33,321 33,364 0% 3,110 2,849 9% 828 808 2% 137,552 130,510 5%
                                     
Key figures                                    
EBITDA margin 20.1% 19.7%   24.3% 24.0%   12.6% 11.8%   6.9% 6.8%         19.1% 18.5%  
EBIT margin 16.0% 15.6%   20.1% 19.7%   9.3% 8.5%   5.8% 5.8%         15.1% 14.5%  
Depreciation and amortization in % of sales 4.2% 4.1%   4.2% 4.4%   3.3% 3.4%   1.1% 1.0%         4.0% 4.0%  
Operating cash flow in % of sales 11.4% 11.9%   15.4% 12.9%   12.3% 9.1%   6.6% 4.7%         12.0% 11.0%  
ROOA 12.5% 12.2%   11.9% 10.2%   7.8% 7.1%   22.2% 22.8%         11.6% 10.5%  

by region


  Europe North America Asia-Pacific Latin America Africa Fresenius Group
€ in millions 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change
The consolidated segment reporting by region is an integral part of the notes. The following notes are an integral part of the consolidated financial statements.
Sales 6,515 6,045 8% 7,020 6,113 15% 1,307 1,088 20% 814 641 27% 316 277 14% 15,972 14,164 13%
contribution to consolidated sales 41% 42%   44% 43%   8% 8%   5% 5%   2% 2%   100% 100%  
EBIT 723 673 7% 1,347 1,092 23% 205 173 18% 107 87 23% 36 29 24% 2,418 2,054 18%
Depreciation and amortization 294 271 8% 265 232 14% 47 36 31% 27 19 42% 6 4 50% 639 562 14%
                                     
Total assets 8,935 7,763 15% 12,152 11,176 9% 1,610 1,233 31% 755 616 23% 125 94 33% 23,577 20,882 13%
Capital expenditure, gross 400 350 14% 223 229 -3% 73 50 46% 52 37 41% 10 5 100% 758 671 13%
Acquisitions, gross 267 136 96% 277 98 183% 89 12 -- 11 13 -15% - 1 -100% 644 260 148%
                                     
Employees (per capita on balance sheet date) 66,179 63,602 4% 46,082 44,590 3% 12,258 10,356 18% 11,726 10,804 9% 1,307 1,158 13% 137,552 130,510 5%

  Europe North America Asia-Pacific Latin America Africa Fresenius Group
€ in millions 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change 2010 2009 Change
The consolidated segment reporting by region is an integral part of the notes. The following notes are an integral part of the consolidated financial statements.
Sales 6,515 6,045 8% 7,020 6,113 15% 1,307 1,088 20% 814 641 27% 316 277 14% 15,972 14,164 13%
contribution to consolidated sales 41% 42%   44% 43%   8% 8%   5% 5%   2% 2%   100% 100%  
EBIT 723 673 7% 1,347 1,092 23% 205 173 18% 107 87 23% 36 29 24% 2,418 2,054 18%
Depreciation and amortization 294 271 8% 265 232 14% 47 36 31% 27 19 42% 6 4 50% 639 562 14%
                                     
Total assets 8,935 7,763 15% 12,152 11,176 9% 1,610 1,233 31% 755 616 23% 125 94 33% 23,577 20,882 13%
Capital expenditure, gross 400 350 14% 223 229 -3% 73 50 46% 52 37 41% 10 5 100% 758 671 13%
Acquisitions, gross 267 136 96% 277 98 183% 89 12 -- 11 13 -15% - 1 -100% 644 260 148%
                                     
Employees (per capita on balance sheet date) 66,179 63,602 4% 46,082 44,590 3% 12,258 10,356 18% 11,726 10,804 9% 1,307 1,158 13% 137,552 130,510 5%

Continue reading:
Notes